Navigation Links
Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
Date:11/25/2008

mbination with Idarubicin and Cytarabine in Patients with

Relapsed/Refractory AML

Session Name: Acute Myeloid Leukemia - Therapy, Excluding Transplantation

Session Date: Tuesday, December 9th, 2008 Presentation Time: 7:45 AM

Session Location: Moscone Center, Room 3020-3022-3024 - West

2008 ASH Annual Meeting - Poster Presentation

Title: Pharmacodynamic Study of Phase 1/2 Trial of the XIAP Antisense

Oligonucleotide (AEG35156) in Combination with Chemotherapy in Patients

with Relapsed/Refractory AML

Abstract: #1943, Poster Board # II-37

Session Date: Sunday, December 7th, 2008

Session Time: 6:00 PM - 8:00 PM

Session Location: Moscone Center, Hall A

About AEG35156

AEG35156, a second generation antisense which targets XIAP, is designed to lower the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemotherapy. Aegera's published data with AEG35156, both in vitro and in vivo, strongly supports this hypothesis, and validates XIAP as a novel oncology drug target. The activity of AEG35156 is currently being explored, in combination, or as a monotherapy, in the following indications: acute myeloid leukemia, non-small cell lung cancer, hepatocarcinoma, and chronic lymphocytic leukemia and indolent B-cell lymphomas. The latter study is being conducted with the financial and scientific support of the Leukemia and Lymphoma Society through their innovative Therapy Acceleration Program.

About Aegera Therapeutics Inc.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. In addition to AEG35156, Aegera has three additional programs in clinical development for the treatment of cancer and neuropathic pain. Details
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
2. Aegera Therapeutics welcomes two experienced executives to its board of directors
3. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
4. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
5. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
6. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
7. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
8. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
9. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
10. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
11. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... LA JOLLA, Calif. , July 29, 2014 /PRNewswire/ ... therapy-based diagnostic and therapeutic company focused on extending the ... have hired Franz Och , Ph.D., an expert ... Chief Data Scientist. Och comes to HLI from Google ... of Google Translate. He will report directly to HLI ...
(Date:7/29/2014)... of researchers has created a new way of ... These surfaces, made by self-assembly of carbon nanotubes, ... including controllable mechanical stiffness and strength, or the ... , "We have demonstrated that mechanical forces can ... three-dimensional microstructures, and that we can independently control ...
(Date:7/29/2014)... 2014 Second generation biofuels are a viable ... fuels. However, as natural gas is very cheap, this is ... not as valuable as they could be in comparison to ... projects, has made it difficult for renewable energy developers to ... the ground. For these reasons, certain companies have shifted their ...
(Date:7/29/2014)... SANTA CLARA, Calif. , July 29, 2014 ... research services agreement with FORMA Therapeutics, Inc., to ... capabilities and proprietary fragment-based lead discovery platform for ... are really excited about the opportunity to work ... the fields of epigenetics and protein homeostasis. FORMA ...
Breaking Biology Technology:Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3A new way to make microstructured surfaces 2Renewable Waste Intelligence: Could Renewable Chemicals Be the Future for the Renewable Energy Industry? 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2
... Products with Herculex(R) XTRA Will Qualify for ... Lower Crop Insurance Rates, ... plant Pioneer(R) brand corn hybrids with the Herculex(R) XTRA,trait, including those ... crop insurance premium reductions in select states in 2009., DuPont ...
... has signed an agreement with AstraZeneca PLC under which Melior’s in-vivo ... activity of selected AstraZeneca compounds. , ... EXTON, ... represents a significant opportunity for Melior to deliver value to AstraZeneca ...
... Product Developed from the VisEn-Merck & Co., Inc. ... Fluorescence Molecular Imaging Agent,Portfolio and Broadens Applications in ... BEDFORD, Mass., Aug. 19 VisEn Medical, ... research through medicine, announced,today the commercial launch of ...
Cached Biology Technology:DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products 2DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products 3VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent 2
(Date:7/29/2014)... 29, 2014 Research and Markets  has ... Intelligence (BI) Market 2014-2018" report to their offering. ... The term BI refers to applications and technologies ... analyzing information about a company,s operations. BI help organizations ... business; for example, metrics on sales, production, and internal ...
(Date:7/29/2014)... to the edge of science, Clment Vidal takes on ... and the End: Does our universe have a beginning ... alone in the universe? What is the role of ... science and committed to philosophical rigor, the book presents ... is not an accident, but may well be the ...
(Date:7/29/2014)... UK overseas territory of Ascension Island, one of the ... a renaissance. , Writing in the journal Biodiversity ... and Ascension Island Government Conservation Department report that the ... Atlantic outpost has increased by more than 500 per ... as 24,000 nests are now estimated to be laid ...
Breaking Biology News(10 mins):Global SaaS-based Business Intelligence (BI) Market 2014-2018 2Book: 'The Beginning and the End' 2Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2
... peak in sight fitness peak, that is for ... Lenski, MSU Hannah Distinguished Professor of Microbiology and Molecular Genetics, ... generating more than 50,000 generations. In a paper published in ... author and MSU graduate student in Lenski,s lab, compares it ...
... genetic signature of respiratory syncytial virus (RSV), the leading cause ... key step toward a better understanding of the immune response ... and a tool that could allow physicians to determine the ... from a team at The Research Institute at Nationwide Children,s ...
... may be more able to cope with dry conditions ... and Colorado State University used a computer model to ... the Amazon rainforest may be more able to withstand ... climate models. Many climate models over predict the ...
Cached Biology News:No peak in sight for evolving bacteria 2Genetic signature identified for RSV, the leading cause of infant hospitalizations worldwide 2Genetic signature identified for RSV, the leading cause of infant hospitalizations worldwide 3Amazon rainforest more able to withstand drought than previously thought 2
... StabilZyme SELECT Stabilizer is an aqueous solution ... other non-toxic stabilizing chemicals in a saline ... a combination of 0.02% methylisothiazolone and 0.02% ... Stabilizer is a diluent and stabilizer for ...
... Lipid adsorption and clarification reagent; ... the purification of antibodies, proteins, nucleic ... has negligible cross-reactivity, and improves downstream ... a solid-phase, non-ionic adsorbent supplied as ...
... Stabilizer is a bovine protein-free alternative to ... aqueous solution that contains non-toxic chemicals in ... 6.6 - 7.2, and does not contain ... activity of antibodies and other biomolecules that ...
A simple, sensitive and reliable method for determining free sulfhydryl content in peptides, protein...
Biology Products: